BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 22849543)

  • 1. LOH at 6q and 10q in fractionated circulating DNA of ovarian cancer patients is predictive for tumor cell spread and overall survival.
    Kuhlmann JD; Schwarzenbach H; Wimberger P; Poetsch M; Kimmig R; Kasimir-Bauer S
    BMC Cancer; 2012 Jul; 12():325. PubMed ID: 22849543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of heterozygosity proximal to the M6P/IGF2R locus is predictive for the presence of disseminated tumor cells in the bone marrow of ovarian cancer patients before and after chemotherapy.
    Kuhlmann JD; Schwarzenbach H; Otterbach F; Heubner M; Wimberger P; Worm KH; Kimmig R; Kasimir-Bauer S
    Genes Chromosomes Cancer; 2011 Aug; 50(8):598-605. PubMed ID: 21563231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative evaluation of cell-free tumor DNA in blood and disseminated tumor cells in bone marrow of patients with primary breast cancer.
    Schwarzenbach H; Pantel K; Kemper B; Beeger C; Otterbach F; Kimmig R; Kasimir-Bauer S
    Breast Cancer Res; 2009; 11(5):R71. PubMed ID: 19772563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A critical evaluation of loss of heterozygosity detected in tumor tissues, blood serum and bone marrow plasma from patients with breast cancer.
    Schwarzenbach H; Müller V; Beeger C; Gottberg M; Stahmann N; Pantel K
    Breast Cancer Res; 2007; 9(5):R66. PubMed ID: 17915011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of heterozygosity at tumor suppressor genes detectable on fractionated circulating cell-free tumor DNA as indicator of breast cancer progression.
    Schwarzenbach H; Eichelser C; Kropidlowski J; Janni W; Rack B; Pantel K
    Clin Cancer Res; 2012 Oct; 18(20):5719-30. PubMed ID: 23014523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of tumor-specific DNA in blood and bone marrow plasma from patients with prostate cancer.
    Schwarzenbach H; Chun FK; Lange I; Carpenter S; Gottberg M; Erbersdobler A; Friedrich MG; Huland H; Pantel K
    Int J Cancer; 2007 Apr; 120(7):1465-71. PubMed ID: 17205532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of platinum-based chemotherapy on circulating nucleic acid levels, protease activities in blood and disseminated tumor cells in bone marrow of ovarian cancer patients.
    Wimberger P; Roth C; Pantel K; Kasimir-Bauer S; Kimmig R; Schwarzenbach H
    Int J Cancer; 2011 Jun; 128(11):2572-80. PubMed ID: 20715113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Loss of heterozygosity at chromosome 3p14, 25 in serum DNA from ovarian cancer patients].
    Zhang H; Li Z; Chen M; Zhang G; Xu K
    Zhonghua Fu Chan Ke Za Zhi; 2002 May; 37(5):298-300. PubMed ID: 12133406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular profiling and prognostic relevance of circulating tumor cells in the blood of ovarian cancer patients at primary diagnosis and after platinum-based chemotherapy.
    Aktas B; Kasimir-Bauer S; Heubner M; Kimmig R; Wimberger P
    Int J Gynecol Cancer; 2011 Jul; 21(5):822-30. PubMed ID: 21613958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of platinum-based chemotherapy on disseminated tumor cells in blood and bone marrow of patients with ovarian cancer.
    Wimberger P; Heubner M; Otterbach F; Fehm T; Kimmig R; Kasimir-Bauer S
    Gynecol Oncol; 2007 Nov; 107(2):331-8. PubMed ID: 17764727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The presence and prognostic impact of apoptotic and nonapoptotic disseminated tumor cells in the bone marrow of primary breast cancer patients after neoadjuvant chemotherapy.
    Hartkopf AD; Taran FA; Wallwiener M; Hagenbeck C; Melcher C; Krawczyk N; Hahn M; Wallwiener D; Fehm T
    Breast Cancer Res; 2013; 15(5):R94. PubMed ID: 24099325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic impact of KI67, p53, human epithelial growth factor receptor 2, topoisomerase IIalpha, epidermal growth factor receptor, and nm23 expression of ovarian carcinomas and disseminated tumor cells in the bone marrow.
    Schindlbeck C; Hantschmann P; Zerzer M; Jahns B; Rjosk D; Janni W; Rack B; Sommer H; Friese K
    Int J Gynecol Cancer; 2007; 17(5):1047-55. PubMed ID: 17433065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of 1p, 19q, and 10q heterozygosity prospectively predicts prognosis of oligodendroglial tumors--towards individualized tumor treatment?
    Ramirez C; Bowman C; Maurage CA; Dubois F; Blond S; Porchet N; Escande F
    Neuro Oncol; 2010 May; 12(5):490-9. PubMed ID: 20156805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pooled analysis of the prognostic relevance of disseminated tumor cells in the bone marrow of patients with ovarian cancer.
    Fehm T; Banys M; Rack B; Janni W; Marth C; Blassl C; Hartkopf A; Trope C; Kimmig R; Krawczyk N; Wallwiener D; Wimberger P; Kasimir-Bauer S
    Int J Gynecol Cancer; 2013 Jun; 23(5):839-45. PubMed ID: 23694981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Explorative investigation of vascular endothelial growth factor receptor expression in primary ovarian cancer and its clinical relevance.
    Wimberger P; Chebouti I; Kasimir-Bauer S; Lachmann R; Kuhlisch E; Kimmig R; Süleyman E; Kuhlmann JD
    Gynecol Oncol; 2014 Jun; 133(3):467-72. PubMed ID: 24713547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Presence of disseminated tumor cells in bone marrow correlates with tumor stage and nodal involvement in cervical cancer patients.
    Fehm T; Banys M; Rack B; Jäger B; Hartkopf A; Taran FA; Janni W
    Int J Cancer; 2014 Feb; 134(4):925-31. PubMed ID: 23921989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of disseminated tumor cells in patients with gynecological cancers.
    Fehm T; Becker S; Bachmann C; Beck V; Gebauer G; Banys M; Wallwiener D; Solomayer EF
    Gynecol Oncol; 2006 Dec; 103(3):942-7. PubMed ID: 16889820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognosis of women with stage IV breast cancer depends on detection of circulating tumor cells rather than disseminated tumor cells.
    Bidard FC; Vincent-Salomon A; Sigal-Zafrani B; Diéras V; Mathiot C; Mignot L; Thiery JP; Sastre-Garau X; Pierga JY
    Ann Oncol; 2008 Mar; 19(3):496-500. PubMed ID: 18187488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection and characterization of circulating microsatellite-DNA in blood of patients with breast cancer.
    Schwarzenbach H; Müller V; Stahmann N; Pantel K
    Ann N Y Acad Sci; 2004 Jun; 1022():25-32. PubMed ID: 15251935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disseminated tumor cells in bone marrow may affect prognosis of patients with gynecologic malignancies.
    Banys M; Solomayer EF; Becker S; Krawczyk N; Gardanis K; Staebler A; Neubauer H; Wallwiener D; Fehm T
    Int J Gynecol Cancer; 2009 Jul; 19(5):948-52. PubMed ID: 19574790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.